CDKN2A and neoplasm: Although elevated levels of ΔNp63α alone are insufficient to confer a tumor phenotype in vivo, we found that ΔNp63α blocks oncogene-induced senescence by inhibiting p16ink4a/p19arf pathways and cooperates with oncogenic v-RasHA to enhance malignant conversion in vivo.